Are you over 18 and want to see adult content?
More Annotations
A complete backup of https://fairfaxunderground.com
Are you over 18 and want to see adult content?
A complete backup of https://aspistrategist.org.au
Are you over 18 and want to see adult content?
A complete backup of https://sporter.com
Are you over 18 and want to see adult content?
A complete backup of https://kentauron.com
Are you over 18 and want to see adult content?
A complete backup of https://installgentoo.com
Are you over 18 and want to see adult content?
A complete backup of https://belstu.by
Are you over 18 and want to see adult content?
A complete backup of https://capetowncycletour.com
Are you over 18 and want to see adult content?
A complete backup of https://ziarulargesul.ro
Are you over 18 and want to see adult content?
A complete backup of https://alltoptenreviews.com
Are you over 18 and want to see adult content?
A complete backup of https://get-drugs-now.com
Are you over 18 and want to see adult content?
A complete backup of https://tadalafilcialispills.com
Are you over 18 and want to see adult content?
A complete backup of https://rhizandatalali.gq
Are you over 18 and want to see adult content?
Favourite Annotations
eUrologia.pl - Urologia, Zabiegi urologiczne, Choroby, Leczenie
Are you over 18 and want to see adult content?
Price, Search, Buy New & Used Cars Online - CarsDirect
Are you over 18 and want to see adult content?
iTechworld - Redback Generators & Jump Starters & Portable Solar Panels
Are you over 18 and want to see adult content?
MIZANULADYAN BLOG | Timbangan Agama-agama lewat pemikiran,analisa dan tulisan
Are you over 18 and want to see adult content?
CgmBet System - a powerful tool for experienced punters
Are you over 18 and want to see adult content?
Text
medicines.
MEDICINES | JAZZ PHARMACEUTICALS We believe all people, including those who live with complex conditions, deserve new and better therapeutic options. As part of our commitment to patients with unmet needs, we continually work to expand the science behind our therapies, acquire rights to develop new medicines, and partner with researchers, academia and other industry leaders to advance molecules with great potential to create CANADA | JAZZ PHARMACEUTICALS Jazz Pharmaceuticals Canada Jazz Pharmaceuticals Canada, Inc. 4080 Confederation Parkway Suite 602 Mississauga, Ontario L5B 0G1 Main Line: 647-946-8801 Main Fax: 647-946-8802 Medical Information Tel: +1 800 520 5568 Email: jazzcamc@dlss.com Drug Safety (to report an adverse event for a Jazz product) Tel: +1 800 520 5568 Jazz Pharmaceuticals Manufacturing and Development 250-887 Great Northern JAZZ’S COMMITMENT TO ALL PATIENTS: NEXT STEPS IN 2021 Acute lymphoblastic leukemia (ALL) is a cancer of the blood and bone marrow that can progress quickly if not treated. Leukemia is the mostcommon cancer in
PATIENT ASSISTANCE
Jazz is committed to improving patient care through unique programs and ongoing collaboration with patients, physicians and advocacygroups.
JAZZ PHARMACEUTICALS TO ACQUIRE GW PHARMACEUTICALS PLC DUBLIN and LONDON, Feb. 3, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and GW Pharmaceuticals plc (Nasdaq: GWPH) today announced the companies have entered into a definitive agreement for Jazz to acquire GW for $220.00 per American Depositary Share (ADS), in the form of $200.00 in cash and $20.00 in Jazz ordinary shares, for a total consideration of $7.2 billion, or IMPROVING PATIENTS' LIVES Today is an exciting and transformative day for Jazz Pharmaceuticals as we complete the acquisition of GW Pharmaceuticals and its U.S. subsidiary, Greenwich Biosciences, a world leader in the science, development and commercialization of regulatory approved cannabinoidmedicines.
MEDICINES | JAZZ PHARMACEUTICALS We believe all people, including those who live with complex conditions, deserve new and better therapeutic options. As part of our commitment to patients with unmet needs, we continually work to expand the science behind our therapies, acquire rights to develop new medicines, and partner with researchers, academia and other industry leaders to advance molecules with great potential to create CANADA | JAZZ PHARMACEUTICALS Jazz Pharmaceuticals Canada Jazz Pharmaceuticals Canada, Inc. 4080 Confederation Parkway Suite 602 Mississauga, Ontario L5B 0G1 Main Line: 647-946-8801 Main Fax: 647-946-8802 Medical Information Tel: +1 800 520 5568 Email: jazzcamc@dlss.com Drug Safety (to report an adverse event for a Jazz product) Tel: +1 800 520 5568 Jazz Pharmaceuticals Manufacturing and Development 250-887 Great Northern JAZZ’S COMMITMENT TO ALL PATIENTS: NEXT STEPS IN 2021 Acute lymphoblastic leukemia (ALL) is a cancer of the blood and bone marrow that can progress quickly if not treated. Leukemia is the mostcommon cancer in
PATIENT ASSISTANCE
Jazz is committed to improving patient care through unique programs and ongoing collaboration with patients, physicians and advocacygroups.
JAZZ PHARMACEUTICALS TO ACQUIRE GW PHARMACEUTICALS PLC DUBLIN and LONDON, Feb. 3, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and GW Pharmaceuticals plc (Nasdaq: GWPH) today announced the companies have entered into a definitive agreement for Jazz to acquire GW for $220.00 per American Depositary Share (ADS), in the form of $200.00 in cash and $20.00 in Jazz ordinary shares, for a total consideration of $7.2 billion, orPATIENT ASSISTANCE
Jazz is committed to improving patient care through unique programs and ongoing collaboration with patients, physicians and advocacygroups.
PIPELINE | JAZZ PHARMACEUTICALS Pipeline PRE-CLINICAL Undisclosed targets Neuroscience CombiPlex Exploratory activities JZP341 (Long-acting Erwinia asparaginase)1 ALL/other hematological malignancies Pan-RAF Inhibitor program Raf & Ras mutant tumors Undisclosed targets Ras/Raf/MAP kinase pathway1 Exosome targets (NRAS and 3 others)1 Hematological malignancies/solid tumors Defibrotide Exploratory activities JAZZ PHARMACEUTICALS COMPLETES ACQUISITION OF GW DUBLIN, May 5, 2021 /PRNewswire/ -- Jazz Pharmaceuticals (Nasdaq: JAZZ) today announced the completion of its acquisition of GW Pharmaceuticals plc (Nasdaq: GWPH) ("GW"), a leader in the science, development and commercialization of cannabinoid-based prescription medicines. "We are excited to welcome our GW colleagues to Jazz as we mark a transformative milestone in creating INVESTORS | JAZZ PHARMACEUTICALS PLC Corporate Overview. Jazz Pharmaceuticals plc (Nasdaq: JAZZ), a global biopharmaceutical company, is dedicated to developing life-changing medicines for people with limited or no options. JAZZ PHARMACEUTICALS CAREERS Jazz has been made aware of fraudulent schemes involving our company name and recruitment. Jazz will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or during telephone, in-person or videointerviews.
JAZZ PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF NEW DRUG DUBLIN, March 25, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) accepted for filing with Priority Review the company's New Drug Application (NDA) seeking marketing approval for JZP-258, an investigational medicine for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age andUNITED STATES
Jazz Pharmaceuticals U.S. Offices 3170 Porter Drive Palo Alto, CA 94304 Tel: 650 496 3777 5750 Fleet Street, Suite 200 Carlsbad, CA 92008 Tel: +1 760 795 2200 2005 Market Street Suite 2100 Philadelphia, PA 19103 Tel: 215 832 3750 For Medical Information Requests in the U.S. please click here. To Report an Adverse EventGERMANY AND AUSTRIA
Jazz Pharmaceuticals Germany GmbH Grillparzerstrasse 18 81675 München Tel: +49 89 41109660 Medical Information Tel: +49 30 56796128 Email: medinfo-de@jazzpharma.com Drug Safety (to report an adverse event for a Jazz product) Tel: +49 30 56796128 Email: aereporting@jazzpharma.com Customer Services Tel: +49 89 41109674 Fax: + 49 89 41109661 Email: customerservices.r3@jazzpharma.com ITALY | JAZZ PHARMACEUTICALS Jazz Healthcare Italy S.r.l Piazza XX Settembre 2 22079 Villa Guardia CO Italy Tel: +39 031 5373200 Fax: +39 031 5375277 Medical Information Tel: +39 0687500850 Email: medinfo-it@jazzpharma.com Drug Safety (to report an adverse event for a Jazz product) Tel: +39 0687500850 Email: medinfo-it@jazzpharma.com Customer Services Tel: +39 031 537 3200 Fax:+39 031 5375277
PRODUCT MONOGRAPH
1 . PRODUCT MONOGRAPH . PrKIDROLASE® (L-asparaginase) 10,000 IU/Vial . Powder for Solution for Intramuscular injection or Intravenous infusion . OTHER ANTINEOPLASTIC AGENTS IMPROVING PATIENTS' LIVES Jazz Pharmaceuticals to Participate in Three Investor Conferences in May 2021. Jazz Pharmaceuticals Completes Acquisition of GW Pharmaceuticals plc. See all News. Jazz Pharmaceuticals is a global biopharmaceutical company dedicated to bringing life-changing medicines to people with limited or no options, so they can live theirlives more fully.
ABOUT | JAZZ PHARMACEUTICALS Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are focused on developing life-changing medicines for people with serious diseases — oftenwith limited or
CANADA | JAZZ PHARMACEUTICALS Jazz Pharmaceuticals Canada Jazz Pharmaceuticals Canada, Inc. 4080 Confederation Parkway Suite 602 Mississauga, Ontario L5B 0G1 Main Line: 647-946-8801 Main Fax: 647-946-8802 Medical Information Tel: +1 800 520 5568 Email: jazzcamc@dlss.com Drug Safety (to report an adverse event for a Jazz product) Tel: +1 800 520 5568 Jazz Pharmaceuticals Manufacturing and Development 250-887 Great Northern CONTACT | JAZZ PHARMACEUTICALS Jazz Pharmaceuticals plc is registered in Ireland, No. 399192. Registered office: Waterloo Exchange, Waterloo Road, Dublin 4 V.A.T. Registration number: 6419192A INVESTORS | JAZZ PHARMACEUTICALS PLC Corporate Overview. Jazz Pharmaceuticals plc (Nasdaq: JAZZ), a global biopharmaceutical company, is dedicated to developing life-changing medicines for people with limited or no options. Our strategy is to create shareholder value by: Growing sales of the existing products in our portfolio, including by identifying new growth opportunities; JAZZ’S COMMITMENT TO ALL PATIENTS: NEXT STEPS IN 2021 For many years, Jazz was the commercial partner to Porton Biopharma Limited (PBL), the owner and manufacturer of Erwinaze/se. However in early 2020, PBL announced its decision to move forward with a new partner, Clinigen, to commercialize and distribute Erwinaze/se from January 1, 2021 onwards. Thus our agreement with PBL ended on December31
JAZZ PHARMACEUTICALS TO ACQUIRE GW PHARMACEUTICALS PLC DUBLIN and LONDON, Feb. 3, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and GW Pharmaceuticals plc (Nasdaq: GWPH) today announced the companies have entered into a definitive agreement for Jazz to acquire GW for $220.00 per American Depositary Share (ADS), in the form of $200.00 in cash and $20.00 in Jazz ordinary shares, for a total consideration of $7.2 billion, or ATHLONE, IRELAND (JAZZ PHARMACEUTICALS IRELAND LIMITED) Athlone, Ireland (Jazz Pharmaceuticals Ireland Limited) The Jazz Pharmaceuticals Ireland Manufacturing and Development facility is located in Monksland, west of Athlone Town, in an area zoned for industrial development by Roscommon County Council, just over 70 miles from our Dublin headquarters. Opened in 2016, it was the first directly owned and operated Jazz facility capable JAZZ PHARMACEUTICALS STOPS ENROLLMENT IN PHASE 3 STUDY DUBLIN, April 29, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that enrollment in the Phase 3 clinical study of defibrotide for the prevention of hepatic veno-occlusive disease (VOD) post-hematopoietic stem-cell transplantation (HSCT) in high-risk or very high-risk patients is being discontinued. Enrollment in the study was stopped early based on the JAZZ PHARMACEUTICALS ANNOUNCES FIRST PATIENT ENROLLED IN DUBLIN, Dec. 30, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled in the pivotal Phase 2/3 clinical study for JZP-458, a recombinant Erwinia asparaginase molecule that uses a novel Pseudomonas fluorescens expression platform. The study, conducted in collaboration with the Children's Oncology Group (COG), is IMPROVING PATIENTS' LIVES Jazz Pharmaceuticals to Participate in Three Investor Conferences in May 2021. Jazz Pharmaceuticals Completes Acquisition of GW Pharmaceuticals plc. See all News. Jazz Pharmaceuticals is a global biopharmaceutical company dedicated to bringing life-changing medicines to people with limited or no options, so they can live theirlives more fully.
ABOUT | JAZZ PHARMACEUTICALS Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are focused on developing life-changing medicines for people with serious diseases — oftenwith limited or
CANADA | JAZZ PHARMACEUTICALS Jazz Pharmaceuticals Canada Jazz Pharmaceuticals Canada, Inc. 4080 Confederation Parkway Suite 602 Mississauga, Ontario L5B 0G1 Main Line: 647-946-8801 Main Fax: 647-946-8802 Medical Information Tel: +1 800 520 5568 Email: jazzcamc@dlss.com Drug Safety (to report an adverse event for a Jazz product) Tel: +1 800 520 5568 Jazz Pharmaceuticals Manufacturing and Development 250-887 Great Northern CONTACT | JAZZ PHARMACEUTICALS Jazz Pharmaceuticals plc is registered in Ireland, No. 399192. Registered office: Waterloo Exchange, Waterloo Road, Dublin 4 V.A.T. Registration number: 6419192A INVESTORS | JAZZ PHARMACEUTICALS PLC Corporate Overview. Jazz Pharmaceuticals plc (Nasdaq: JAZZ), a global biopharmaceutical company, is dedicated to developing life-changing medicines for people with limited or no options. Our strategy is to create shareholder value by: Growing sales of the existing products in our portfolio, including by identifying new growth opportunities; JAZZ’S COMMITMENT TO ALL PATIENTS: NEXT STEPS IN 2021 For many years, Jazz was the commercial partner to Porton Biopharma Limited (PBL), the owner and manufacturer of Erwinaze/se. However in early 2020, PBL announced its decision to move forward with a new partner, Clinigen, to commercialize and distribute Erwinaze/se from January 1, 2021 onwards. Thus our agreement with PBL ended on December31
JAZZ PHARMACEUTICALS TO ACQUIRE GW PHARMACEUTICALS PLC DUBLIN and LONDON, Feb. 3, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and GW Pharmaceuticals plc (Nasdaq: GWPH) today announced the companies have entered into a definitive agreement for Jazz to acquire GW for $220.00 per American Depositary Share (ADS), in the form of $200.00 in cash and $20.00 in Jazz ordinary shares, for a total consideration of $7.2 billion, or ATHLONE, IRELAND (JAZZ PHARMACEUTICALS IRELAND LIMITED) Athlone, Ireland (Jazz Pharmaceuticals Ireland Limited) The Jazz Pharmaceuticals Ireland Manufacturing and Development facility is located in Monksland, west of Athlone Town, in an area zoned for industrial development by Roscommon County Council, just over 70 miles from our Dublin headquarters. Opened in 2016, it was the first directly owned and operated Jazz facility capable JAZZ PHARMACEUTICALS STOPS ENROLLMENT IN PHASE 3 STUDY DUBLIN, April 29, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that enrollment in the Phase 3 clinical study of defibrotide for the prevention of hepatic veno-occlusive disease (VOD) post-hematopoietic stem-cell transplantation (HSCT) in high-risk or very high-risk patients is being discontinued. Enrollment in the study was stopped early based on the JAZZ PHARMACEUTICALS ANNOUNCES FIRST PATIENT ENROLLED IN DUBLIN, Dec. 30, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled in the pivotal Phase 2/3 clinical study for JZP-458, a recombinant Erwinia asparaginase molecule that uses a novel Pseudomonas fluorescens expression platform. The study, conducted in collaboration with the Children's Oncology Group (COG), is CANADA | JAZZ PHARMACEUTICALS Jazz Pharmaceuticals Canada Jazz Pharmaceuticals Canada, Inc. 4080 Confederation Parkway Suite 602 Mississauga, Ontario L5B 0G1 Main Line: 647-946-8801 Main Fax: 647-946-8802 Medical Information Tel: +1 800 520 5568 Email: jazzcamc@dlss.com Drug Safety (to report an adverse event for a Jazz product) Tel: +1 800 520 5568 Jazz Pharmaceuticals Manufacturing and Development 250-887 Great PIPELINE | JAZZ PHARMACEUTICALS Pipeline PRE-CLINICAL Undisclosed targets Neuroscience CombiPlex Exploratory activities JZP341 (Long-acting Erwinia asparaginase)1 ALL/other hematological malignancies Pan-RAF Inhibitor program Raf & Ras mutant tumors Undisclosed targets Ras/Raf/MAP kinase pathway1 Exosome targets (NRAS and 3 others)1 Hematological malignancies/solid tumors Defibrotide Exploratory activities CELATOR PHARMACEUTICALS Careers: jazz.talent@jazzpharma.com. For Medical Information Requests related to Celator investigational products please call us at 1-800-520-5568 or email us at jazzpharma@medcomsol.com. For Adverse Events/Drug Complaints related to Celator investigational products click here. Clinical sites may report adverse events by Fax to609.243.0202.
JAZZ PHARMACEUTICALS CAREERS Jazz has been made aware of fraudulent schemes involving our company name and recruitment. Jazz will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or during telephone, in-person or videointerviews.
JAZZ PHARMACEUTICALS COMPLETES ACQUISITION OF GW DUBLIN, May 5, 2021 /PRNewswire/ -- Jazz Pharmaceuticals (Nasdaq: JAZZ) today announced the completion of its acquisition of GW Pharmaceuticals plc (Nasdaq: GWPH) ("GW"), a leader in the science, development and commercialization of cannabinoid-based prescription medicines. "We are excited to welcome our GW colleagues to Jazz as we mark a transformative milestone in creating LEADERSHIP | JAZZ PHARMACEUTICALS Mr. Cozadd co-founded Jazz Pharmaceuticals, Inc. in 2003 and has served as our Chairman and Chief Executive Officer since April 2009. From 1991 until 2001, he held various positions with ALZA Corporation, a pharmaceutical company acquired by Johnson & Johnson, most recently as Executive Vice President and Chief Operating Officer, with responsibility for research and development, JAZZ PHARMACEUTICALS PRESENTS 18 ABSTRACTS IN SLEEP DUBLIN, June 9, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 13 abstracts sponsored by Jazz Pharmaceuticals and five abstracts from investigator-sponsored trials will be presented at SLEEP 2021, the 35 th annual meeting of the Associated Professional Sleep Societies (APSS) from June 10-13, 2021. "Jazz continues to be committed toUNITED STATES
Jazz Pharmaceuticals U.S. Offices 3170 Porter Drive Palo Alto, CA 94304 Tel: 650 496 3777 5750 Fleet Street, Suite 200 Carlsbad, CA 92008 Tel: +1 760 795 2200 2005 Market Street Suite 2100 Philadelphia, PA 19103 Tel: 215 832 3750 For Medical Information Requests in the U.S. please click here. To Report an Adverse EventMETHODOLOGICAL NOTE
Metodología para la publicación Jazz Pharmaceuticals (en adelante, la «Compañía») publicará todas las transferencias de valor realizadas a profesionales sanitarios (en adelante, los «HCP», por sus siglas en inglés) y a organizaciones sanitarias (en adelante, las HCO», por sus siglas en inglés) de conformidad con el Código de prácticas de Farmaindustria, la Asociación delGERMANY AND AUSTRIA
Jazz Pharmaceuticals Germany GmbH Grillparzerstrasse 18 81675 München Tel: +49 89 41109660 Medical Information Tel: +49 30 56796128 Email: medinfo-de@jazzpharma.com Drug Safety (to report an adverse event for a Jazz product) Tel: +49 30 56796128 Email: aereporting@jazzpharma.com Customer Services Tel: +49 89 41109674 Fax: + 49 89 41109661 Email: customerservices.r3@jazzpharma.com IMPROVING PATIENTS' LIVES Jazz Pharmaceuticals to Participate in Three Investor Conferences in May 2021. Jazz Pharmaceuticals Completes Acquisition of GW Pharmaceuticals plc. See all News. Jazz Pharmaceuticals is a global biopharmaceutical company dedicated to bringing life-changing medicines to people with limited or no options, so they can live theirlives more fully.
MEDICINES | JAZZ PHARMACEUTICALS Neuroscience. As a long-time leader in sleep medicine, Jazz has been at the forefront of providing therapies and support for our patients living with serious, debilitating neurologic disorders. More recently we have expanded into additional disease areas with high unmet needs, including rare, severe childhood-onset epilepsy, through our CANADA | JAZZ PHARMACEUTICALS Jazz Pharmaceuticals Canada Jazz Pharmaceuticals Canada, Inc. 4080 Confederation Parkway Suite 602 Mississauga, Ontario L5B 0G1 Main Line: 647-946-8801 Main Fax: 647-946-8802 Medical Information Tel: +1 800 520 5568 Email: jazzcamc@dlss.com Drug Safety (to report an adverse event for a Jazz product) Tel: +1 800 520 5568 Jazz Pharmaceuticals Manufacturing and Development 250-887 Great Northern JAZZ’S COMMITMENT TO ALL PATIENTS: NEXT STEPS IN 2021 For many years, Jazz was the commercial partner to Porton Biopharma Limited (PBL), the owner and manufacturer of Erwinaze/se. However in early 2020, PBL announced its decision to move forward with a new partner, Clinigen, to commercialize and distribute Erwinaze/se from January 1, 2021 onwards. Thus our agreement with PBL ended on December31
JAZZ PHARMACEUTICALS TO ACQUIRE GW PHARMACEUTICALS PLC DUBLIN and LONDON, Feb. 3, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and GW Pharmaceuticals plc (Nasdaq: GWPH) today announced the companies have entered into a definitive agreement for Jazz to acquire GW for $220.00 per American Depositary Share (ADS), in the form of $200.00 in cash and $20.00 in Jazz ordinary shares, for a total consideration of $7.2 billion, orCORPORATE GIVING
Our Focus. We view our global corporate giving as an opportunity for Jazz to help improve patients’ lives by filling unmet needs, demonstrating our commitment to the communities we serve, and making an impact through meaningful support to organizations, initiatives, and causes that reflect our mission, values and strategic focus. JAZZ PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF NEW DRUG DUBLIN, March 25, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) accepted for filing with Priority Review the company's New Drug Application (NDA) seeking marketing approval for JZP-258, an investigational medicine for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and JAZZ PHARMACEUTICALS STOPS ENROLLMENT IN PHASE 3 STUDY DUBLIN, April 29, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that enrollment in the Phase 3 clinical study of defibrotide for the prevention of hepatic veno-occlusive disease (VOD) post-hematopoietic stem-cell transplantation (HSCT) in high-risk or very high-risk patients is being discontinued. Enrollment in the study was stopped early based on theGERMANY AND AUSTRIA
Jazz Pharmaceuticals Germany GmbH Grillparzerstrasse 18 81675 München Tel: +49 89 41109660 Medical Information Tel: +49 30 56796128 Email: medinfo-de@jazzpharma.com Drug Safety (to report an adverse event for a Jazz product) Tel: +49 30 56796128 Email: aereporting@jazzpharma.com Customer Services Tel: +49 89 41109674 Fax: + 49 89 41109661 Email: customerservices.r3@jazzpharma.com PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION … PRODUCT MONOGRAPH . INCLUDING PATIENT MEDICATION INFORMATION . C XYREM. sodium oxybate oral solution . 500 mg/mL . CNS Depressant . Jazz Pharmaceuticals Ireland Limited IMPROVING PATIENTS' LIVES Jazz Pharmaceuticals to Participate in Three Investor Conferences in May 2021. Jazz Pharmaceuticals Completes Acquisition of GW Pharmaceuticals plc. See all News. Jazz Pharmaceuticals is a global biopharmaceutical company dedicated to bringing life-changing medicines to people with limited or no options, so they can live theirlives more fully.
MEDICINES | JAZZ PHARMACEUTICALS Neuroscience. As a long-time leader in sleep medicine, Jazz has been at the forefront of providing therapies and support for our patients living with serious, debilitating neurologic disorders. More recently we have expanded into additional disease areas with high unmet needs, including rare, severe childhood-onset epilepsy, through our CANADA | JAZZ PHARMACEUTICALS Jazz Pharmaceuticals Canada Jazz Pharmaceuticals Canada, Inc. 4080 Confederation Parkway Suite 602 Mississauga, Ontario L5B 0G1 Main Line: 647-946-8801 Main Fax: 647-946-8802 Medical Information Tel: +1 800 520 5568 Email: jazzcamc@dlss.com Drug Safety (to report an adverse event for a Jazz product) Tel: +1 800 520 5568 Jazz Pharmaceuticals Manufacturing and Development 250-887 Great Northern JAZZ’S COMMITMENT TO ALL PATIENTS: NEXT STEPS IN 2021 For many years, Jazz was the commercial partner to Porton Biopharma Limited (PBL), the owner and manufacturer of Erwinaze/se. However in early 2020, PBL announced its decision to move forward with a new partner, Clinigen, to commercialize and distribute Erwinaze/se from January 1, 2021 onwards. Thus our agreement with PBL ended on December31
JAZZ PHARMACEUTICALS TO ACQUIRE GW PHARMACEUTICALS PLC DUBLIN and LONDON, Feb. 3, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and GW Pharmaceuticals plc (Nasdaq: GWPH) today announced the companies have entered into a definitive agreement for Jazz to acquire GW for $220.00 per American Depositary Share (ADS), in the form of $200.00 in cash and $20.00 in Jazz ordinary shares, for a total consideration of $7.2 billion, orCORPORATE GIVING
Our Focus. We view our global corporate giving as an opportunity for Jazz to help improve patients’ lives by filling unmet needs, demonstrating our commitment to the communities we serve, and making an impact through meaningful support to organizations, initiatives, and causes that reflect our mission, values and strategic focus. JAZZ PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF NEW DRUG DUBLIN, March 25, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) accepted for filing with Priority Review the company's New Drug Application (NDA) seeking marketing approval for JZP-258, an investigational medicine for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and JAZZ PHARMACEUTICALS STOPS ENROLLMENT IN PHASE 3 STUDY DUBLIN, April 29, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that enrollment in the Phase 3 clinical study of defibrotide for the prevention of hepatic veno-occlusive disease (VOD) post-hematopoietic stem-cell transplantation (HSCT) in high-risk or very high-risk patients is being discontinued. Enrollment in the study was stopped early based on theGERMANY AND AUSTRIA
Jazz Pharmaceuticals Germany GmbH Grillparzerstrasse 18 81675 München Tel: +49 89 41109660 Medical Information Tel: +49 30 56796128 Email: medinfo-de@jazzpharma.com Drug Safety (to report an adverse event for a Jazz product) Tel: +49 30 56796128 Email: aereporting@jazzpharma.com Customer Services Tel: +49 89 41109674 Fax: + 49 89 41109661 Email: customerservices.r3@jazzpharma.com PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION … PRODUCT MONOGRAPH . INCLUDING PATIENT MEDICATION INFORMATION . C XYREM. sodium oxybate oral solution . 500 mg/mL . CNS Depressant . Jazz Pharmaceuticals Ireland Limited PIPELINE | JAZZ PHARMACEUTICALS Pipeline PRE-CLINICAL Undisclosed targets Neuroscience CombiPlex Exploratory activities JZP341 (Long-acting Erwinia asparaginase)1 ALL/other hematological malignancies Pan-RAF Inhibitor program Raf & Ras mutant tumors Undisclosed targets Ras/Raf/MAP kinase pathway1 Exosome targets (NRAS and 3 others)1 Hematological malignancies/solid tumors Defibrotide Exploratory activities INVESTORS | JAZZ PHARMACEUTICALS PLC Corporate Overview. Jazz Pharmaceuticals plc (Nasdaq: JAZZ), a global biopharmaceutical company, is dedicated to developing life-changing medicines for people with limited or no options. Our strategy is to create shareholder value by: Growing sales of the existing products in our portfolio, including by identifying new growth opportunities;PATIENT ASSISTANCE
Jazz is committed to improving patient care through unique programs and ongoing collaboration with patients, physicians and advocacygroups.
JAZZ PHARMACEUTICALS CAREERS Jazz has been made aware of fraudulent schemes involving our company name and recruitment. Jazz will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or during telephone, in-person or videointerviews.
JAZZ PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF NEW DRUG DUBLIN, March 25, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) accepted for filing with Priority Review the company's New Drug Application (NDA) seeking marketing approval for JZP-258, an investigational medicine for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and JAZZ PHARMACEUTICALS CAREERS Pay equity – it is simply the right thing to do. At Jazz, we strive to achieve pay equity in every country in which we operate — for roles entailing substantially similar work with respect to skill, effort and responsibilities, we consider multiple factors including external market data, individual performance and internal pay equity pursuant to our compensation philosophy and in keeping JAZZ PHARMACEUTICALS CAREERS Cookies are used on this site to assist in continually improving the candidate experience and all the interaction data we store of our visitors is anonymous. ITALY | JAZZ PHARMACEUTICALS Jazz Healthcare Italy S.r.l Piazza XX Settembre 2 22079 Villa Guardia CO Italy Tel: +39 031 5373200 Fax: +39 031 5375277 Medical Information Tel: +39 0687500850 Email: medinfo-it@jazzpharma.com Drug Safety (to report an adverse event for a Jazz product) Tel: +39 0687500850 Email: medinfo-it@jazzpharma.com Customer Services Tel: +39 031 537 3200 Fax:+39 031 5375277
CL-JULIA-DAVERNE
Julia Daverne, a Specialty Sales Consultant for the Sleep Business Unit in the Washington, DC Metro Area, joined Jazz in October 2007. She started her sales career in New York, where she worked first for Honeywell Inc. on Long Island, then Rhone-Poulenc Rorer (RPR), inBrooklyn.
PRODUCT MONOGRAPH
1 . PRODUCT MONOGRAPH . PrKIDROLASE® (L-asparaginase) 10,000 IU/Vial . Powder for Solution for Intramuscular injection or Intravenous infusion . OTHER ANTINEOPLASTIC AGENTS IMPROVING PATIENTS' LIVES Jazz Pharmaceuticals to Participate in Three Investor Conferences in May 2021. Jazz Pharmaceuticals Completes Acquisition of GW Pharmaceuticals plc. See all News. Jazz Pharmaceuticals is a global biopharmaceutical company dedicated to bringing life-changing medicines to people with limited or no options, so they can live theirlives more fully.
MEDICINES | JAZZ PHARMACEUTICALS Neuroscience. As a long-time leader in sleep medicine, Jazz has been at the forefront of providing therapies and support for our patients living with serious, debilitating neurologic disorders. More recently we have expanded into additional disease areas with high unmet needs, including rare, severe childhood-onset epilepsy, through our ABOUT | JAZZ PHARMACEUTICALS Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are focused on developing life-changing medicines for people with serious diseases — oftenwith limited or
CANADA | JAZZ PHARMACEUTICALS Jazz Pharmaceuticals Canada Jazz Pharmaceuticals Canada, Inc. 4080 Confederation Parkway Suite 602 Mississauga, Ontario L5B 0G1 Main Line: 647-946-8801 Main Fax: 647-946-8802 Medical Information Tel: +1 800 520 5568 Email: jazzcamc@dlss.com Drug Safety (to report an adverse event for a Jazz product) Tel: +1 800 520 5568 Jazz Pharmaceuticals Manufacturing and Development 250-887 Great Northern INVESTORS | JAZZ PHARMACEUTICALS PLC Corporate Overview. Jazz Pharmaceuticals plc (Nasdaq: JAZZ), a global biopharmaceutical company, is dedicated to developing life-changing medicines for people with limited or no options. Our strategy is to create shareholder value by: Growing sales of the existing products in our portfolio, including by identifying new growth opportunities; JAZZ PHARMACEUTICALS CAREERS Jazz has been made aware of fraudulent schemes involving our company name and recruitment. Jazz will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or during telephone, in-person or videointerviews.
JAZZ PHARMACEUTICALS TO ACQUIRE GW PHARMACEUTICALS PLC DUBLIN and LONDON, Feb. 3, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and GW Pharmaceuticals plc (Nasdaq: GWPH) today announced the companies have entered into a definitive agreement for Jazz to acquire GW for $220.00 per American Depositary Share (ADS), in the form of $200.00 in cash and $20.00 in Jazz ordinary shares, for a total consideration of $7.2 billion, or JAZZ PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF NEW DRUG DUBLIN, March 25, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) accepted for filing with Priority Review the company's New Drug Application (NDA) seeking marketing approval for JZP-258, an investigational medicine for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and ITALY | JAZZ PHARMACEUTICALSJAZZ PHARMACEUTICALS NARCOLEPSYJAZZ PHARMACEUTICALS PIPELINEJAZZ PHARMACEUTICALS REGULATORYJAZZ PHARMACEUTICALS XYREM Jazz Healthcare Italy S.r.l Piazza XX Settembre 2 22079 Villa Guardia CO Italy Tel: +39 031 5373200 Fax: +39 031 5375277 Medical Information Tel: +39 0687500850 Email: medinfo-it@jazzpharma.com Drug Safety (to report an adverse event for a Jazz product) Tel: +39 0687500850 Email: medinfo-it@jazzpharma.com Customer Services Tel: +39 031 537 3200 Fax:+39 031 5375277
CL-JULIA-DAVERNE
Julia Daverne, a Specialty Sales Consultant for the Sleep Business Unit in the Washington, DC Metro Area, joined Jazz in October 2007. She started her sales career in New York, where she worked first for Honeywell Inc. on Long Island, then Rhone-Poulenc Rorer (RPR), inBrooklyn.
IMPROVING PATIENTS' LIVES Jazz Pharmaceuticals to Participate in Three Investor Conferences in May 2021. Jazz Pharmaceuticals Completes Acquisition of GW Pharmaceuticals plc. See all News. Jazz Pharmaceuticals is a global biopharmaceutical company dedicated to bringing life-changing medicines to people with limited or no options, so they can live theirlives more fully.
MEDICINES | JAZZ PHARMACEUTICALS Neuroscience. As a long-time leader in sleep medicine, Jazz has been at the forefront of providing therapies and support for our patients living with serious, debilitating neurologic disorders. More recently we have expanded into additional disease areas with high unmet needs, including rare, severe childhood-onset epilepsy, through our ABOUT | JAZZ PHARMACEUTICALS Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are focused on developing life-changing medicines for people with serious diseases — oftenwith limited or
CANADA | JAZZ PHARMACEUTICALS Jazz Pharmaceuticals Canada Jazz Pharmaceuticals Canada, Inc. 4080 Confederation Parkway Suite 602 Mississauga, Ontario L5B 0G1 Main Line: 647-946-8801 Main Fax: 647-946-8802 Medical Information Tel: +1 800 520 5568 Email: jazzcamc@dlss.com Drug Safety (to report an adverse event for a Jazz product) Tel: +1 800 520 5568 Jazz Pharmaceuticals Manufacturing and Development 250-887 Great Northern INVESTORS | JAZZ PHARMACEUTICALS PLC Corporate Overview. Jazz Pharmaceuticals plc (Nasdaq: JAZZ), a global biopharmaceutical company, is dedicated to developing life-changing medicines for people with limited or no options. Our strategy is to create shareholder value by: Growing sales of the existing products in our portfolio, including by identifying new growth opportunities; JAZZ PHARMACEUTICALS CAREERS Jazz has been made aware of fraudulent schemes involving our company name and recruitment. Jazz will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or during telephone, in-person or videointerviews.
JAZZ PHARMACEUTICALS TO ACQUIRE GW PHARMACEUTICALS PLC DUBLIN and LONDON, Feb. 3, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and GW Pharmaceuticals plc (Nasdaq: GWPH) today announced the companies have entered into a definitive agreement for Jazz to acquire GW for $220.00 per American Depositary Share (ADS), in the form of $200.00 in cash and $20.00 in Jazz ordinary shares, for a total consideration of $7.2 billion, or JAZZ PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF NEW DRUG DUBLIN, March 25, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) accepted for filing with Priority Review the company's New Drug Application (NDA) seeking marketing approval for JZP-258, an investigational medicine for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and ITALY | JAZZ PHARMACEUTICALSJAZZ PHARMACEUTICALS NARCOLEPSYJAZZ PHARMACEUTICALS PIPELINEJAZZ PHARMACEUTICALS REGULATORYJAZZ PHARMACEUTICALS XYREM Jazz Healthcare Italy S.r.l Piazza XX Settembre 2 22079 Villa Guardia CO Italy Tel: +39 031 5373200 Fax: +39 031 5375277 Medical Information Tel: +39 0687500850 Email: medinfo-it@jazzpharma.com Drug Safety (to report an adverse event for a Jazz product) Tel: +39 0687500850 Email: medinfo-it@jazzpharma.com Customer Services Tel: +39 031 537 3200 Fax:+39 031 5375277
CL-JULIA-DAVERNE
Julia Daverne, a Specialty Sales Consultant for the Sleep Business Unit in the Washington, DC Metro Area, joined Jazz in October 2007. She started her sales career in New York, where she worked first for Honeywell Inc. on Long Island, then Rhone-Poulenc Rorer (RPR), inBrooklyn.
ABOUT | JAZZ PHARMACEUTICALS Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are focused on developing life-changing medicines for people with serious diseases — oftenwith limited or
CONTACT | JAZZ PHARMACEUTICALS Jazz Pharmaceuticals plc is registered in Ireland, No. 399192. Registered office: Waterloo Exchange, Waterloo Road, Dublin 4 V.A.T. Registration number: 6419192APRODUCTS (US)
Products available in the United States. Please visit our product websites to view complete prescribing information, including a BOXED Warning for Xyrem ®, Vyxeos ™, Prialt ® and FazaСlo ®. The product information provided is intended only for residents of the United States. To report an adverse event or a product complaint, orto request
JAZZ’S COMMITMENT TO ALL PATIENTS: NEXT STEPS IN 2021 For many years, Jazz was the commercial partner to Porton Biopharma Limited (PBL), the owner and manufacturer of Erwinaze/se. However in early 2020, PBL announced its decision to move forward with a new partner, Clinigen, to commercialize and distribute Erwinaze/se from January 1, 2021 onwards. Thus our agreement with PBL ended on December31
JAZZ PHARMACEUTICALS CAREERS Pay equity – it is simply the right thing to do. At Jazz, we strive to achieve pay equity in every country in which we operate — for roles entailing substantially similar work with respect to skill, effort and responsibilities, we consider multiple factors including external market data, individual performance and internal pay equity pursuant to our compensation philosophy and in keeping JAZZ PHARMACEUTICALS CAREERS Cookies are used on this site to assist in continually improving the candidate experience and all the interaction data we store of our visitors is anonymous. ITALY | JAZZ PHARMACEUTICALS Jazz Healthcare Italy S.r.l Piazza XX Settembre 2 22079 Villa Guardia CO Italy Tel: +39 031 5373200 Fax: +39 031 5375277 Medical Information Tel: +39 0687500850 Email: medinfo-it@jazzpharma.com Drug Safety (to report an adverse event for a Jazz product) Tel: +39 0687500850 Email: medinfo-it@jazzpharma.com Customer Services Tel: +39 031 537 3200 Fax:+39 031 5375277
GERMANY AND AUSTRIA
Jazz Pharmaceuticals Germany GmbH Grillparzerstrasse 18 81675 München Tel: +49 89 41109660 Medical Information Tel: +49 30 56796128 Email: medinfo-de@jazzpharma.com Drug Safety (to report an adverse event for a Jazz product) Tel: +49 30 56796128 Email: aereporting@jazzpharma.com Customer Services Tel: +49 89 41109674 Fax: + 49 89 41109661 Email: customerservices.r3@jazzpharma.com PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION … PRODUCT MONOGRAPH . INCLUDING PATIENT MEDICATION INFORMATION . C XYREM. sodium oxybate oral solution . 500 mg/mL . CNS Depressant . Jazz Pharmaceuticals Ireland Limited REMOTE SUPPORT PORTAL Submit your issue and download BeyondTrust Remote Support. Copyright 2002-2019 BeyondTrust Corporation. Redistribution Prohibited.Contact Us
* About
* Leadership
* Board of Directors* Global Footprint
* Canada
* France and Belgium * Germany and Austria * United Kingdom and Ireland* Italy
* Spain and Portugal* Nordic Region
* United States
* Countries Supplied through Partners* History
* Corporate Ethics
* Corporate Development* Partnering
* Manufacturing
* Villa Guardia, Italy (Gentium S.r.l) * Athlone, Ireland (Jazz Pharmaceuticals Ireland Limited)* Medicines
* Our Medicines
* Drug Safety
* Medical Information* Science
* Pipeline
* Clinical Trials
* Plain Language Summaries* Expanded Access
* Independent Scientific Research* Responsibility
* Patient Assistance* Disease Education
* Corporate Giving
* Medical Education
* Transfers of Value in Europe* News
* Press Release Archive* Events Archive
* Our Stories
* Investors
* Events / Presentations* Stock Information
* SEC Filings
* GAAP To Non-GAAP Reconciliations* Annual Reports
* Quarterly Results
* Analyst Coverage
* Information Request* FAQs
* Other Information
* Careers
Life-Changing Medicines. Redefining Possibilities. COVID-19 Response Jazz is implementing a robust continuity plan in response to the COVID-19 pandemic. LEARN MOREpatient story
Life Before and After Stem Cell Transplant After receiving treatment for acute myeloid leukemia, Steve underwent a stem cell transplant to decrease the odds of the cancer returning. Following the transplant, his journey was complicated with a diagnosis of veno-occlusive disease. Steve and Crystal’s StoryOur science
Understanding Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma There are several types of blood cancer, including acute lymphoblastic leukemia and lymphoblastic lymphoma, which are among the mostdifficult to treat.
Learn More
News and Events
November 17, 2020
Jazz Pharmaceuticals Appoints Jennifer Cook and Mark Smith, M.D. to its Board of DirectorsNovember 10, 2020
Jazz Pharmaceuticals Announces Participation at Jefferies Virtual London Healthcare ConferenceNovember 5, 2020
Data at ASH 2020 Annual Meeting Highlights Jazz Pharmaceuticals’ Commitment to Advancing Hematology/Oncology Research Jazz strives to create a workplace culture that supports a diverse, multicultural workforce and provides an inclusive environment where all employees are empowered to contribute and succeed.See all News
Jazz Pharmaceuticals is a global biopharmaceutical company dedicated to bringing life-changing medicines to people with limited or no options, so they can live their lives more fully.More About Jazz
Living Our Values
Careers at Jazz
Clinical Trials
Learn More
By unlocking biopharmaceutical discoveries to develop novel medicines, we are giving thousands of people around the world the opportunity to redefine what’s possible.Our Medicines
* About
* Leadership
* Board of Directors* Global Footprint
* History
* Corporate Ethics
* Corporate Development* Manufacturing
* News
* Careers
* Medicines
* Our Medicines
* Drug Safety
* Medical Information* Science
* Pipeline
* Clinical Trials
* Expanded Access
* Independent Scientific Research* Responsibility
* COVID-19 Response
* Patient Assistance* Disease Education
* Corporate Giving
* Medical Education
* Transfers of Value in Europe* Investors
* Events / Presentations* Stock Information
* SEC Filings
* GAAP To Non-GAAP Reconciliations* Annual Reports
* Quarterly Results
* Analyst Coverage
* Information Request* FAQs
* Other Information
l
2020 Jazz Pharmaceuticals, Inc. All Rights Reserved.* Privacy Statement
* Terms of Use
* Social Media Global Guidelines* Sitemap
Thank you for contacting Jazz Pharmaceuticals Corporate Development &Partnering
Sending data...
CONTACT CORPORATE DEVELOPMENT / PARTNERING PERSONAL INFORMATION _(All fields are required)_ PLEASE PROVIDE DETAILS ON THIS OPPORTUNITYFirst Name:
Full Name:
Title:
Organization:
Address Line 1:
Address Line 2:
City:
State: - select state - no state Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware District of Columbia Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington West Virginia Wisconsin Wyoming American Samoa Guam Marshall Islands Micronesia Northern Marianas Palau Puerto RicoVirgin Islands
Zip Code:
Country:
Phone Number:
Email Address:
Therapeutic Area:
Indication:
Mechanism of Action: Highest Development Phase: Overview of Opportunity including non-confidential information supporting the rationale for the molecular target, proof-of-concept for a particular technology and other relevant details.Send
This website uses cookies to help us provide you with a more responsive and personalized service. By using this website without changing your cookie settings, you agree to our use of cookies. For more information on how we use cookies and how to delete or block the use of cookies, please see our PRIVACY STATEMENT . By clicking on Accept you consent to our use of cookies.Reject Accept
The information on this page is intended for visitors inContinue
You are leaving the Home pageLeave
You are leaving the Home pageLeave
This page is for U.S. residents only. By clicking on this page, you confirm you are a U.S. resident.Continue
Thank you for visiting JazzPharma.com. The site you are about to visit is maintained by a third party who is solely responsible for its content; Jazz Pharmaceuticals is not responsible for the content or privacy practices of any third-party websites. Click Cancel to returnor OK to continue.
Ok Cancel
You are now leaving www.JazzPharma.com. Thank you for visiting. The information on the website you are entering is intended for visitors in the United States only.Ok Cancel
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0